Publication: Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease
Issued Date
2021-07-01
Resource Type
ISSN
20426313
20426305
20426305
Other identifier(s)
2-s2.0-85108431098
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Comparative Effectiveness Research. Vol.10, No.10 (2021), 801-813
Suggested Citation
Philippe Godeberge, Parvez Sheikh, Varut Lohsiriwat, Abel Jalife, Yury Shelygin Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease. Journal of Comparative Effectiveness Research. Vol.10, No.10 (2021), 801-813. doi:10.2217/cer-2021-0038 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78079
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease
Abstract
Hemorrhoidal disease (HD) is common in adults. Treatment is largely conservative, although more invasive procedures may be required. Venoactive drugs such as micronized purified flavonoid fraction (MPFF) are widely used, but a recent and comprehensive review of supporting evidence is lacking. In acute HD, MPFF can reduce HD symptoms such as bleeding, pain, anal discomfort, anal discharge and pruritus. In patients undergoing surgery, postoperative adjunct MPFF consistently reduces pain, bleeding duration and use of analgesia. MPFF treatment is appropriate and effective both as a first-line conservative treatment and as a postoperative adjunct treatment. MPFF reduces the duration of hospital stay following surgery, facilitating a return to normal activity and improving quality of life. MPFF may also prevent HD recurrence.